QSYMIA Medication Guide and Safety Considerations

Introduction to QSYMIA Safety

The American College of Clinical Pharmacology recommends that patients taking QSYMIA (phentermine and topiramate extended-release) be aware of the teratogenicity risk, which requires monthly pregnancy testing at home after initial healthcare professional verification, due to the topiramate component causing birth defects 1, 2
The National Institute of Diabetes and Digestive and Kidney Diseases indicates that QSYMIA can cause cardiovascular effects, including increased heart rate and blood pressure, requiring monitoring 1, 3

The Endocrine Society notes that QSYMIA can cause psychiatric and cognitive adverse effects, including depression, suicidal ideation, concentration/memory impairment, and anxiety 1, 2
The American Society of Nephrology recommends that patients taking QSYMIA be monitored for metabolic acidosis, which requires electrolyte and creatinine monitoring before and during treatment 1
The American Academy of Ophthalmology warns that QSYMIA can cause acute angle-closure glaucoma, which can lead to acute myopia and ocular pain 1, 3

The National Institute of Mental Health advises that QSYMIA is contraindicated with MAOIs, requiring at least 14 days between discontinuation 1, 3
The American Urological Association notes that QSYMIA can increase the risk of kidney stone formation, which can lead to acute nephrolithiasis 1
The American College of Clinical Pharmacology recommends a discontinuation protocol for QSYMIA, which should not be stopped abruptly and requires tapering over at least 1 week 1
The Society of Obstetricians and Gynaecologists warns that QSYMIA can cause drug interactions, including altered metabolism of estrogen and progestins, which can lead to menstrual spotting in women taking birth control pills 1

The American Pharmacists Association recommends that pharmacists provide the medication guide with every prescription fill, which serves as ongoing reinforcement of critical safety information, particularly important given the cognitive impairment that can occur with this medication 1, 2
The National Institute of Child Health and Human Development advises that patients need repeated reminders about monthly home pregnancy testing requirements and the absolute contraindication in pregnancy 1, 2

Treatment should be discontinued if a patient has not achieved at least 5% weight loss after 12 weeks at the maximum dose of 15/92 mg daily, as this indicates inadequate response, according to the Clinical Gastroenterology and Hepatology guidelines 4